Progress!!
Biomark receives OK for lung cancer treatment protocol
2016-03-29 08:17 ET - News Release
Mr. Rashid Ahmed reports
BIOMARK RECEIVES APPROVAL FOR ITS LUNG CANCER TREATMENT PROTOCOL
Biomark Diagnostics Inc. has now completed its response to lung cancer treatment protocol and has successfully been granted approval by both Health Canada and the Ethics Review Board. Having received both approvals for this protocol, the company can now commence its preliminary pilot study at CancerCare Manitoba, expected to commence late April, 2016.
President and chief executive officer of Biomark Rashid Ahmed stated: "Health Canada approval for our lung cancer treatment protocol is an important achievement for Biomark. Our technology offers real clinical value and offers physicians a cheaper and faster prognosis biomarker for prediction of chemotherapy response, as well as a positive/negative indicator of the prognosis for patients with a lung cancer diagnosis. This is a large and underserved market that Biomark intends to additionally capture. We anticipate 2016 to be a milestone year for the company with the completion of the 200 patient clinical trial and the commercialization of its early detection red alert technology."
Biomark's technology platform is robust and can be used as a cancer management system with application in early detection, measuring response to both drug and surgical treatment, and potentially for serial cancer monitoring. Biomark is investigating and continually developing multiple clinical applications of its platform metabolomics-based technology. The company has recently closed the first tranche of private placement of over $400,000 to be used for the continuation of the company's clinical trials, marketing initiatives and general working capital.
We seek Safe Harbor.